Free tool
FAERS Monitor: Sutent
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021938 or its brand name (Sutent, Sunitinib Malate). Reports on generic versions are filed under their own applications.
Reports
39,149
Serious
30,215
77% of reports
Hospitalization
11,531
Death reported
11,688
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death7,452
- diarrhoea4,422
- fatigue4,195
- disease progression3,912
- nausea3,121
- asthenia2,461
- decreased appetite2,316
- vomiting2,211
- neoplasm progression2,020
- hypertension1,805
- dysgeusia1,696
- weight decreased1,589
- malaise1,585
- stomatitis1,465
- palmar-plantar erythrodysaesthesia syndrome1,455
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2006 | 777 |
| 2007 | 810 |
| 2008 | 838 |
| 2009 | 1,585 |
| 2010 | 3,423 |
| 2011 | 2,736 |
| 2012 | 3,177 |
| 2013 | 2,701 |
| 2014 | 3,143 |
| 2015 | 3,905 |
| 2016 | 3,384 |
| 2017 | 2,986 |
| 2018 | 2,531 |
| 2019 | 2,041 |
| 2020 | 1,594 |
| 2021 | 1,172 |
| 2022 | 1,066 |
| 2023 | 508 |
| 2024 | 314 |
| 2025 | 269 |
| 2026 | 188 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,015,010 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| palmar-plantar erythrodysaesthesia syndromeSignal | 1,455 | 35.7 | 33.9 | 46,026 |
| neoplasm progressionSignal | 2,020 | 33.1 | 31.7 | 59,264 |
| disease progressionSignal | 3,912 | 18.3 | 17.8 | 62,332 |
| stomatitisSignal | 1,465 | 13.3 | 12.6 | 16,259 |
| dysgeusiaSignal | 1,696 | 12.5 | 12.0 | 17,631 |
| decreased appetiteSignal | 2,316 | 5.4 | 5.2 | 8,310 |
| deathSignal | 7,452 | 4.7 | 4.6 | 22,279 |
| hypertensionSignal | 1,805 | 4.6 | 4.4 | 5,106 |
| diarrhoeaSignal | 4,422 | 3.7 | 3.6 | 8,920 |
| astheniaSignal | 2,461 | 3.5 | 3.4 | 4,518 |
| weight decreasedSignal | 1,589 | 3.1 | 2.9 | 2,232 |
| fatigueSignal | 4,195 | 2.9 | 2.8 | 5,411 |
| vomitingSignal | 2,211 | 2.5 | 2.4 | 2,088 |
| nauseaSignal | 3,121 | 2.1 | 2.1 | 1,918 |
| malaise | 1,585 | 1.9 | 1.9 | 740 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.